Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China
Authors:
- 4 October 2007
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 1 (3) , 373-381
Abstract
This randomized, double-blind, placebo-controlled study was undertaken to evaluate the efficacy and safety of entecavir in Chinese patients with lamivudine-refractory chronic hepatitis B.Keywords
This publication has 28 references indexed in Scilit:
- Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentAntimicrobial Agents and Chemotherapy, 2007
- Hepatology issues in Asia: Perspectives from regional leadersJournal of Gastroenterology and Hepatology, 2004
- Four years of lamivudine treatment in Chinese patients with chronic hepatitis BJournal of Gastroenterology and Hepatology, 2004
- Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutantsJournal of Hepatology, 2004
- Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to LamivudineAntimicrobial Agents and Chemotherapy, 2004
- Clinical Experience With LamivudineSeminars in Liver Disease, 2002
- The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisationJournal of Clinical Virology, 2002
- Prevention and control of hepatitis B in ChinaJournal of Medical Virology, 2002
- The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceJournal of Clinical Investigation, 2001
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999